Tipping P G, Holdsworth S R
Clin Exp Immunol. 1985 Mar;59(3):555-63.
Macrophages have recently been identified as the predominant mediators of the glomerular injury in acute serum sickness (AcSS) in rabbits. Corticosteroids have been shown to prevent this lesion, but the mechanism of this effect is unknown. As corticosteroids are potent anti-macrophage agents, the effect of prednisolone treatment (2 mg/kg/day) on glomerular macrophage accumulation and injury was assessed in rabbits developing AcSS. Eleven untreated animals all developed a proliferative endocapillary glomerulonephritis (mean 71.7 +/- 1.9 sem cells per glomerular cross section, c/gcs) with glomerular macrophage accumulation (46.3 +/- 5.7 macrophages per glomerulus, macs/glom) and proteinuria (555 +/- 379 mg/24 h). Eight animals were treated with prednisolone commencing not more than 48 h prior to immune elimination (IE). Glomerular injury was markedly attenuated with significantly less cellular proliferation (49.1 +/- 2.1 c/gcs, P less than .005), fewer macrophages within glomeruli (10.5 +/- 7.7 macs/glom, P less than .005) and minimal proteinuria (19.3 +/- 5.5 mg/24 h, P less than 0.01). Treatment did not alter the amount of circulating BSA-anti-BSA immune complex; its time of IE (11.1 +/- 0.4 days treated, 11.4 +/- 0.4 days untreated) its renal deposition (2.36 +/- 0.64 micrograms BSA/g renal cortex treated, 2.66 +/- 0.52 mg BSA/g renal cortex untreated) or its glomerular localization. These results indicate that prednisolone treatment can effectively reduce the glomerular injury of AcSS. This effect is not dependent on any alteration of immune complex formation or deposition, but involves reduction of macrophage accumulation at the inflammatory site.
巨噬细胞最近被确定为兔急性血清病(AcSS)肾小球损伤的主要介质。皮质类固醇已被证明可预防这种病变,但其作用机制尚不清楚。由于皮质类固醇是强效抗巨噬细胞药物,因此在发生AcSS的兔中评估了泼尼松龙治疗(2mg/kg/天)对肾小球巨噬细胞积聚和损伤的影响。11只未治疗的动物均发生了增殖性毛细血管内肾小球肾炎(每个肾小球横截面平均71.7±1.9个半细胞,c/gcs),伴有肾小球巨噬细胞积聚(每个肾小球46.3±5.7个巨噬细胞,macs/glom)和蛋白尿(555±379mg/24h)。8只动物在免疫清除(IE)前不超过48小时开始用泼尼松龙治疗。肾小球损伤明显减轻,细胞增殖明显减少(49.1±2.1c/gcs,P<0.005),肾小球内巨噬细胞减少(10.5±7.7macs/glom,P<0.005),蛋白尿极少(19.3±5.5mg/24h,P<0.01)。治疗未改变循环中牛血清白蛋白-抗牛血清白蛋白免疫复合物的量;其IE时间(治疗组为11.1±0.4天,未治疗组为11.4±0.4天)、其在肾脏的沉积(治疗组为肾皮质2.36±0.64μg牛血清白蛋白/g,未治疗组为2.66±0.52mg牛血清白蛋白/g肾皮质)或其在肾小球的定位。这些结果表明,泼尼松龙治疗可有效减轻AcSS的肾小球损伤。这种作用不依赖于免疫复合物形成或沉积的任何改变,而是涉及炎症部位巨噬细胞积聚的减少。